Procter & Gamble Health Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 19 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹10.7K Cr
The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes. Company has delivered consistent high single digit sales growth (~8%) and average profit growth of 9% over past 5 years. - Net profit margin expanded by 200 basis points over past 5 years. - Return on equity increased 3 times during this period, reflecting resilience and execution. - Fiscal year ended March 31, 2025 reported profit after tax of Rs.
From Procter & Gamble Health Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹5,828
Market Cap
₹10.7K Cr
P/E Ratio
32.8
How does Procter & Gamble Health Ltd rank in Pharmaceuticals & Biotechnology?
Compare Procter & Gamble Health Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹370 Cr, net profit ₹95 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes.
- →They achieved strong single-digit top-line growth and double-digit bottom-line growth in the recent fiscal year.
- →Focus remains on increasing penetration in categories like Nerve Care, Vitamin E, and Nasal Decongestant with market leadership in Vitamin E.
- →There is significant runway for growth by serving unserved and underserved healthcare practitioners (HCPs) and consumers.
- →The integrated growth strategy combining product superiority, retail execution, and HCP engagement is viewed as the right approach to sustain growth.
- →Export markets, such as Sri Lanka, show strong potential with over 30% growth recently.
- →Ongoing investments in product innovation and productivity indicate a commitment to both volume and margin expansion.
- →Overall, the company expects sustained balanced growth driven by consumer value, superior products, and expanding market access.
📈 Profitability & Margins
🏗️ Capital Expenditure Plans
- →The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments.
- →The company emphasizes ongoing investments in raising superiority standards across product formulations, packaging, communication, and retail execution to serve consumer needs better.
- →Productivity efforts (achieving savings of over Rs. 40 crore this fiscal) are highlighted as fuel to reinvest in superiority across five vectors.
- →There is a focus on investments to improve products and launch new superior products, as well as investing in capabilities and innovative go-to-market models.
- →They invest in healthcare practitioner engagement and collaborations with healthcare organizations to create a holistic ecosystem.
- →No specific future capex plans or monetary allocations are provided.
- →Price hike principles and pricing strategies are aligned with regulations but no concrete capital spending plans were disclosed.
💰 Fundraising & Capital Structure
- →The transcript on page 9 does not mention any current or future plans for fundraising through debt or equity.
- →When asked about price hikes and financial strategies, the company emphasized adherence to pricing strategy and DPCO regulations without commenting on future plans.
- →The company focuses on pricing products according to value and consumer willingness rather than discussing capital raising.
- →Overall, no information or indication was provided regarding raising funds via debt or equity during the call.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q4 FY25 results?
The company has delivered consistent high single-digit sales growth over the past 5 years despite market volatility and operational changes. Company has delivered consistent high single digit sales growth (~8%) and average profit growth of 9% over past 5 years. - Net profit margin expanded by 200 basis points over past 5 years. - Return on equity increased 3 times during this period, reflecting resilience and execution. - Fiscal year ended March 31, 2025 reported profit after tax of Rs.
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹10,731 Cr. Investors should review the full earnings analysis for detailed insights.
Is Procter & Gamble Health Ltd planning capital expenditure?
The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic investments. - The company emphasizes ongoing investments in raising superiority standards across product formulations, packaging, communication, and retail execution to serve consumer needs better. - Productivity efforts (achieving savings of over Rs.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.